oasis 1 oral semaglutide 50 mg nejm 2023 obesity taken once per day in adults with overweight or (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial Semaglutide GLP-1 Receptor Agonist Research

Obesity is a major risk factor for high blood pressure, so by promoting weight loss, semaglutide often leads to a meaningful drop in blood pressure, including for people whose readings remain high despite taking blood pressure medications

A prior late-stage trial published in December showed the drug helped obese or overweight patients with one or more comorbidities, but not type-2 diabetes, lower their weight by 22.7% after 68 weeks, also below the 25% expected

Expert insight from our panelists: Morgan Lee, PhD, MPH, CPH Vice President, Research & Marketing Scott Halperin, PharmD Vice President, Employer Pharmacy Benefit Consulting Steve Altenburger, PharmD Senior Pharmacy Benefit Consultant

My colleague T.J

GLP-1 (glucagon-like peptide-1) plays a key role in appetite regulation

What the clinical data shows on belly fat Controlled trials have demonstrated reductions of 15 to 20% in visceral adipose tissue over 26 weeks of treatment